Author

Michael A. Farrar

Masonic Cancer CenterORCID 0000-0002-5569-0366Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Enoc Granados CentenoiD· 2 shared Hrishi VenkateshiD· 2 shared Lynn M. Heltemes-HarrisiD· 2 shared Sean I. TracyiD· 2 shared Allison HaaningiD· 1 shared Beau R. WebberiD· 1 shared Elizabeth C MorganiD· 1 shared Gregory HubbardiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Enoc Granados CentenoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Leukemia escapes immunity by imposing a Type-1 regulatory program on neoantigen-specific CD4+ T cells.

Hrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, Miriam Arroyo, Lynn M. Heltemes-Harris, Todd Philip Knutson, Yinjie Qiu, Allison Haaning, Beau R. Webber, Veronika Bachanová, Michael A. Farrar, Sean I. Tracy

This paper shows leukemia induces neoantigen-specific CD4+ T cells to become regulatory (Tr1) cells, which suppress cytotoxic T cells and promote relapse, and repolarizing these cells to Th1 states eradicates residual disease.

Blood · Sep 4, 2025Peer-reviewedCancer Biology

PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE

Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centeno, Lynn M. Heltemes-Harris, Gregory Hubbard, Taylor L Maiers, Thamotharampillai Dileepan, Sean I. Tracy, Michael A. Farrar

This study compares the effects of nilotinib and dasatinib on anti-leukemia immune responses when combined with PD-L1 blockade, finding that nilotinib synergizes with PD-L1 blockade to prevent relapse while dasatinib does not.

bioRxiv · Jul 2, 2025 · PreprintImmunology